

Liquid biopsy profiling solutions

From biomarker discovery to clinical trial assay support, Labcorp Oncology offers a broad portfolio of products and services focused on liquid biopsy profiling. Our solutions help pharmaceutical and biotech companies accelerate innovation, unlock value and bring the power of precision medicine to more patients.

Current landscape for liquid biopsy profiling


Liquid biopsy is driving a new era in oncology drug development. Less invasive and faster to process than traditional tissue samples, liquid biopsy profiling can augment traditional tissue-based testing workflows and findings. A paired tissue-plasma strategy can enhance testing access and flexibility, increase eligible patient populations and uncover more therapeutically targetable mutations that tissue-only testing may miss. Bringing new possibilities to biopharma discovery, development and diagnostics, Labcorp's liquid biopsy profiling solutions can help you deliver safer, more effective and appropriate therapies to the right patients.

PLASMA COMPLETE

Comprehensive genomic profiling for biomarker discovery and analysis

Identify novel and emerging biomarkers with plasma complete, an end-to-end, sample-to-answer liquid biopsy CGP solution for cancer research.

- **Genes covered:** 521
- **Analysis:** cfDNA
- **Sample input:** 25 ng recommended (10 ng minimum)
- **Sequencing coverage:** 20,000x total coverage
- **Turnaround time:** 10-14 days for prospective analysis; retrospective analysis is dependent upon batch sizing
- **Gene list:** View full list [here](#)
- **PGDx corporate & lab certifications:** ISO 13485:2016, ISO 15189:2012, CAP/CLIA, NY State CLEP



PLASMA COMPLETE CONTINUED



Reliable

Identify somatic mutations with high accuracy and sensitivity even with low DNA input



Comprehensive

Evaluate 521 pan solid tumor-related genes across all variant classes, including SNVs, indels, bTMB, MSI, LOH, and select amplifications and translocations



Potential for Expanded Use

Built under design control to withstand the rigors of the FDA approval process for potential use in prospective clinical trials

PLASMA COMPLETE + MATCHED NORMAL | RUO SERVICE

Confident classifications with matched normal analysis

The integrated analysis of cfDNA and matched leukocyte DNA enables the differentiation of tumor-derived (somatic) variants from germline alterations and variants associated with clonal hematopoiesis. This may improve the accuracy of liquid biopsy profiling, molecular response assessment and clonal evaluation analyses. In a benchmark study, blood samples were analyzed from 27 patients representing seven different solid tumor types. Figure 1 shows the distribution of reclassified variants through matched normal analysis.





Figure 1. More accurate classification of tumor-derived variants with matched normal analysis.

PLASMA FOCUS™

Targeted liquid biopsy test for patient stratification in clinical trials

A targeted liquid biopsy test that focuses on FDA-approved and guideline-driven biomarkers for patients with advanced solid cancers, Plasma Focus delivers actionable results to inform cohort stratification and clinical trial enrollment.

- **Genes covered:** 33
- **Analysis:** cfDNA
- **Sample input:** 25 ng recommended
- **Sequencing coverage:** 25,000x total coverage
- **Turnaround time:** 7-10 days
- **Gene list:** View full list [here](#)
- **PGDx corporate & lab certifications:** ISO 13485:2016, ISO 15189:2012, CAP/CLIA, NY State CLEP



Sensitive and Specific

Highly sensitive and featuring a highly curated gene panel focused on FDA-approved biomarkers



Fast

Sample collection and processing for results in 7-10 days when rapid results are needed



CDx Ready

Built under design control to withstand the rigors of the FDA approval process

PLASMA FOCUS | RUO

This targeted assay is also available as part of an RUO service provided out of our lab in Baltimore, Maryland.



WHY LABCORP

One partner to achieve your next cancer breakthrough

At Labcorp, we provide industry-leading biopharma services and solutions to help you discover, develop and deliver life-changing therapies that increase the potential to save the lives of people around the world. Built on a reputation for scientific and technical excellence and an unmatched global network, we can support you at every stage of the cancer research continuum.

- **Deep Scientific Knowledge and Experience:** Access comprehensive and specialized oncology expertise with our integrated medical, scientific, regulatory and statistical teams
- **Development Acceleration:** Reduce development time and risk with end-to-end support from discovery through diagnostic commercialization
- **Data-Driven Insights:** Optimize biomarker-driven development with unparalleled data and real-world evidence
- **Global Laboratory Network:** Ensure day-one readiness with global drug and diagnostic co-development and test commercialization capabilities



Partnered with biopharma on 10 of 16 of oncology drugs approved by the FDA in 2022



Supported CDx development for PD-L1, HER-2, KRAS, EGFR, BRAF, ALK and more



Experience supporting clinical trial testing for 2,000+ trials across various tumor types

Contact us

Contact our biopharma team to see how we can help you accelerate your precision oncology program.

Learn more at www.oncology.labcorp.com/biopharma-partners